Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 1
2005 2
2006 1
2007 2
2008 1
2009 1
2010 7
2011 7
2012 5
2013 6
2014 6
2015 16
2016 6
2017 2
2018 4
2019 2
2020 3
2021 1
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.
Lehtonen M, Sormunen J, Luukkaala T, Marttila T, McDermott R, Joensuu T, Lehtinen I, Ginman C, Kellokumpu-Lehtinen PL. Lehtonen M, et al. Among authors: joensuu t. Acta Oncol. 2022 Aug;61(8):963-971. doi: 10.1080/0284186X.2022.2098680. Epub 2022 Jul 18. Acta Oncol. 2022. PMID: 35847998 Clinical Trial.
Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer.
Liikanen I, Basnet S, Quixabeira DCA, Taipale K, Hemminki O, Oksanen M, Kankainen M, Juhila J, Kanerva A, Joensuu T, Tähtinen S, Hemminki A. Liikanen I, et al. Among authors: joensuu t. J Immunother Cancer. 2022 Feb;10(2):e003490. doi: 10.1136/jitc-2021-003490. J Immunother Cancer. 2022. PMID: 35193929 Free PMC article.
A Deep Learning-Based Automated CT Segmentation of Prostate Cancer Anatomy for Radiation Therapy Planning-A Retrospective Multicenter Study.
Kiljunen T, Akram S, Niemelä J, Löyttyniemi E, Seppälä J, Heikkilä J, Vuolukka K, Kääriäinen OS, Heikkilä VP, Lehtiö K, Nikkinen J, Gershkevitsh E, Borkvel A, Adamson M, Zolotuhhin D, Kolk K, Pang EPP, Tuan JKL, Master Z, Chua MLK, Joensuu T, Kononen J, Myllykangas M, Riener M, Mokka M, Keyriläinen J. Kiljunen T, et al. Among authors: joensuu t. Diagnostics (Basel). 2020 Nov 17;10(11):959. doi: 10.3390/diagnostics10110959. Diagnostics (Basel). 2020. PMID: 33212793 Free PMC article.
Eye Symptoms in a Patient With Prostate Cancer.
Kairemo K, Kangasmäki A, Joensuu T, Seregard S. Kairemo K, et al. Among authors: joensuu t. Clin Nucl Med. 2020 May;45(5):370-371. doi: 10.1097/RLU.0000000000002982. Clin Nucl Med. 2020. PMID: 32149800
Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension.
Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A; FinnProstate Group. Hackman G, et al. Among authors: joensuu t. Eur Urol. 2019 Nov;76(5):586-595. doi: 10.1016/j.eururo.2019.07.001. Epub 2019 Jul 30. Eur Urol. 2019. PMID: 31375279 Clinical Trial.
177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.
von Eyben FE, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP. von Eyben FE, et al. Among authors: joensuu t. Oncotarget. 2019 Mar 29;10(25):2451-2461. doi: 10.18632/oncotarget.26789. eCollection 2019 Mar 29. Oncotarget. 2019. PMID: 31069008 Free PMC article.
69 results